No Differences in Cellular Immune Responses between Asymptomatic HIV Type 1- and Type 2-Infected Gambian Patients

Journal of Infectious Diseases

Volumn 189, Issue 3, 2004, Pages 498-505

  Jaye, Assan ^a   Sarge Njie, Ramu ^a   Van Der Loeff, Maarten Schim ^a   Todd, Jim ^b   Alabi, Abraham ^a   Sabally, Shehu ^a   Corrah, Tumani ^a   Whittle, Hilton ^a  

^a MEDICAL RESEARCH COUNCIL LABORATORIES   (Gambia)

^b LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; CHROMIUM 51; GAMMA INTERFERON;

ADULT; ARTICLE; CELL MEDIATED LYMPHOLYSIS; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; ENZYME ASSAY; ENZYME LINKED IMMUNOSPOT ASSAY; ENZYME RELEASE; FEMALE; GAMBIA; HELPER CELL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 2; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTERMETHOD COMPARISON; LYMPHOCYTE COUNT; LYMPHOCYTE PROLIFERATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; T LYMPHOCYTE; VIRUS LOAD;

ADULT; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CYTOTOXICITY, IMMUNOLOGIC; FEMALE; GAMBIA; HIV INFECTIONS; HIV-1; HIV-2; HUMANS; IMMUNITY, CELLULAR; INTERFERON TYPE II; MALE; T-LYMPHOCYTES; VIRAL LOAD;

EID: 1142285203     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/381185     Document Type: Article

References (36)

1. Goulder P, Price D, Nowak M, Rowland-Jones S, Phillips R, McMichael A. Co-evolution of human immunodeficiency virus and cytotoxic T lymphocyte responses. Immunol Rev 1997; 159:17-29.
2. + cytotoxic T lymphocyte responses to lentiviruses and herpesviruses. Curr Opin Immunol 2001; 13:479-82.
3. Ogg GS, Jin X, Bonhoeffer S, et al. Quantitation of HIV-1-specific cytotoxic T lymphocytes and plasma load of viral RNA. Science 1998; 279:2103-6.
4. Wilson JD, Ogg GS, Allen RL, et al. Direct visualisation of HIV-specific cytotoxic T lymphocytes during primary infection. AIDS 2000; 14:225-33.
5. Zajac AJ, Blattman JN, Murali-Krishna K, et al. Viral immune evasion due to persistence of activated T cells without effector function. J Exp Med 1998; 188:2205-13.
6. + cell numbers and clinical staging. J Clin Invest 1989; 84:1892-9.
7. Rosenberg ES, Billingsley JM, Caliendo AM, et al. Vigorous HIV-1-specific CD4 T cell responses associated with control of viremia. Science 1997; 278:1447-50.
8. Kalams SA, Buchbinder SP, Rosenberg ES, et al. Association between virus-specific cytotoxic T-lymphocyte and helper responses in human immunodeficiency virus type 1 infection. J Virol 1999; 73:6715-20.
9. Rosenberg ES, Altfeld M, Poon SH, et al. Immune control of HIV-1 after treatment of acute infection. Nature 2000; 407:523-6.
10. Gotch F, McAdam SN, Allsopp CE, et al. Cytotoxic T cells in HIV-2 seropositive Gambians: identification of a virus specific MHC-restricted peptide epitope. J Immunol 1993; 151:3361-9.
11. Ariyoshi K, Cham F, Berry N, et al. HIV-2-specific cytotoxic T lymphocyte activity is inversely related to proviral load. AIDS 1995; 9:555-9.
12. Bertoletti A, Cham F, McAdam S, et al. Cytotoxic T cells from HIV-2 infected patients frequently cross-react with different HIV-1 clades. J Virol 1998; 72:2439-48.
13. Pinto LA, Covas MJ, Victorino RM. T-helper cross-reactivity to viral recombinant proteins in HIV-2 infected patients. AIDS 1993; 7:1389-91.
14. Pinto LA, Covas MI, Victorino RM. T helper reactivity to SIV gag synthetic peptides in HIV-2 infected individuals. J Med Virol 1995; 47:139-44.
15. Ariyoshi K, Berry N, Wilkins A, et al. A community based study of HIV-2 provirus load in a rural village in West Africa. J Infect Dis 1996; 173:245-8.
16. Berry N, Ariyoshi K, Jaffar S, et al. Low peripheral blood viral HIV-2 RNA in individuals with high CD4 percentage differentiates HIV-2 from HIV-1 infection. J Hum Virol 1998; 1:457-68.
17. Jaffar S, Wilkins A, Ngom PT, et al. Rate of decline of percentage CD4 cells is faster in HIV-1 than in HIV-2 infection. J Acquir Immune Defic Syndr Hum Retrovirol 1997; 16:327-32.
18. Whittle HC, Ariyoshi K, Rowland-Jones S. HIV-2 and T cell recognition. Curr Opin Immunol 1998; 10:382-7.
19. McAdam S, Kaleebu P, Krausa, P, et al. Cross-clade recognition of p55 by cytotoxic T lymphocytes in HIV-1 infection. AIDS 1998; 12:571-9.
20. Bennett S, Riley EM. The statistical analysis of data from immunoepidemiological studies. J Immunol Methods 1992; 146:229-39.
21. Popper SJ, Sarr AD, Travers KU, et al. Lower human immunodeficiency virus type 2 viral load reflects the difference in pathogenecity of HIV-1 and HIV-2. J Infect Dis 1999; 180:1116-21.
22. O'Donovan D, Ariyoshi K, Milligan P, et al. Maternal plasma viral RNA levels determine marked differences in mother-to-child transmission rates of HIV-1 and HIV-2 in The Gambia: MRC/Gambia Government/University College London Medical School working group on Mother-Child Transmission of HIV. AIDS 2000; 14:441-8.
23. Andersson S, Norrgren H, da Silva Z, et al. Plasma viral load in HIV-1 and HIV-2 singly and dually infected individuals in Guinea-Bissau, West Africa: significantly lower plasma virus set point in HIV-2 infection than in HIV-1 infection. Arch Intern Med 2000; 160:3286-93.
24. Shanmugam V, Switzer WM, Nkengasong JN, et al. Lower HIV-2 plasma viral loads may explain differences between the natural histories of HIV-1 and HIV-2 infections. J Acquir Immune Defic Syndr 2000; 24:257-63.
25. Alabi AS, Jaffar S, Ariyoshi K, et al. Plasma viral load, CD4 cell percentage, HLA and survival of HIV-1, HIV-2 and dually infected Gambian patients. AIDS 2003; 17:1513-20.
26. Nixon DF, Townsend ARM, Elvin JG, Rizza CR, Gallaway I, McMichael AJ. HIV-1 gag-specific CTL defined with recombinant vaccinia virus and synthetic peptides. Nature 1988; 336:484-7.
27. Schramm B, Penn ML, Palacios EH, Grant RM, Kirchhoff F, Goldsmith MA. Cytopathicity of human deficiency virus type 2 (HIV-2) in human lymphoid tissue is co-receptor dependent and comparable to that of HIV-1. J Virol 2000; 74:9594-600.
28. + T cell responses cannot be predicted by major histocompatibility complex class I haplotype. J Virol 2000; 74:9144-51.
29. Cham F, Heyndrickx L, Janssens W, et al. Study of HIV type 1 gag/ env variability in The Gambia, using a multiplex DNA polymerase chain reaction. AIDS Res Hum Retroviruses 2000; 16:1915-9.
30. + T cells using an Elispot assay. J Immunol Methods 1995; 181:45-54.
31. Betts MR, Krowka JF, Kepler TB, et al. Human immunodeficiency virus type 1-specific cytotoxic T lymphocyte activity is inversely correlated with HIV type 1 viral load in HIV type 1-infected long-term survivors. AIDS Res Hum Retroviruses 1999; 15:1219-28.
32. Musey L, Hughes J, Schacker T, Shea T, Corey L, McElrath MJ. Cytotoxic T cell responses, viral load and disease progression in early human immunodeficiency virus type 1 infection. N Engl J Med 1997; 337:1267-74.
33. + T cell responses: relationship to viral load in untreated HIV infection. J Virol 2001; 75:11983-91.
34. Sousa AE, Chaves AF, Lourecro A, Victorino RMM. Comparison of the frequency of interleukin (IL)-2-, interferon-γ-, and IL-4-producing T cells in 2 diseases, human immunodeficiency virus type 1 and 2, with distinct clinical outcomes. J Infect Dis 2001; 184:552-9.
35. + T cells produce antiviral cytokines but are impaired in cytolytic function. J Exp Med 2000; 192:63-75.
36. Lopes R, Jaye A, Dorrell L, et al. T cell receptor heterogeneity correlates with enhanced potential of CTL to recognise mutated epitopes in HIV-2 compared to HIV-1 infection. J Immunol 2003; 171:307-16.